Midwest Trust Co Acquires New Holdings in Charles River Laboratories International, Inc. $CRL

Midwest Trust Co bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,141 shares of the medical research company’s stock, valued at approximately $3,966,000.

Other hedge funds also recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its holdings in shares of Charles River Laboratories International by 407.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock valued at $150,142,000 after buying an additional 800,762 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock worth $353,750,000 after acquiring an additional 516,521 shares in the last quarter. Royal Bank of Canada grew its stake in Charles River Laboratories International by 304.7% in the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock valued at $94,484,000 after acquiring an additional 472,606 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Charles River Laboratories International by 144.3% in the first quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock worth $82,007,000 after acquiring an additional 321,789 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 5.1% during the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after purchasing an additional 208,586 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $167.99 on Monday. The firm has a market capitalization of $8.27 billion, a P/E ratio of -126.31, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $168.00 and its two-hundred day moving average price is $155.67. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $222.10.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter last year, the firm posted $2.59 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on CRL shares. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their price objective for the company from $142.00 to $195.00 in a research report on Tuesday, September 9th. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the company a “neutral” rating in a report on Thursday. Robert W. Baird raised shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $178.00 to $199.00 in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. Finally, Baird R W raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $186.93.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).